



PRIOR AUTHORIZATION POLICY

- POLICY:** Inflammatory Conditions – Kineret Prior Authorization
- Kineret® (anakinra subcutaneous injection – Swedish Orphan Biovitrim)

REVIEW DATE: 02/28/2024; selected revision 4/24/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Kineret, an interleukin-1 (IL-1) blocker, is indicated for the following uses:¹

- **Cryopyrin-associated periodic syndromes (CAPS)**, for treatment of neonatal-onset multisystem inflammatory disease (NOMID).
- **Deficiency of interleukin-1 receptor antagonist (DIRA)** treatment.
- **Rheumatoid arthritis**, to reduce the signs and symptoms and slow the progression of structural damage with moderately to severely active disease in adults who have failed one or more disease-modifying antirheumatic drugs (DMARDs); Kineret can be used ± DMARDs, other than tumor necrosis factor inhibitors (TNFis).

In addition to the FDA-approved uses, Kineret has been granted Emergency Use Authorization for treatment of Coronavirus disease 2019 (COVID-19) in hospitalized adults with positive viral testing with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR).²²

Guidelines

Kineret is used for treatment of a variety of inflammatory conditions. The European Alliance of Associations for Rheumatology (EULAR) and American College of Rheumatology (ACR) [2021] provide treatment guidelines for IL-1 mediated autoinflammatory diseases and indicate IL-blocking therapy has become the preferred treatment.²⁴ The guidelines also provide additional diagnosis-specific treatment recommendations:

- **CAPS:** CAPS encompasses three rare genetic syndromes (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and NOMID or chronic infantile neurological cutaneous and articular syndrome) that are thought to be one condition along a spectrum of disease severity.^{2,3} The EULAR/ACR guidelines state IL-1 blockers are recommended as standard of care across the spectrum of disease for improved symptom control and reduced systemic and tissue/organ inflammation.²⁴ The dose and/or frequency of administration should be adjusted to control disease activity, normalize markers of systemic inflammation, and for appropriate weight gain and development in the growing patient. In many cases, patients with CAPS reported an immediate clinical response to Kineret with rash, fever, and arthritis disappearing within a few days and not recurring during follow-up.⁴ Dramatic and persistent normalization of inflammatory markers and hematologic tests have also been achieved.
- **DIRA:** Dysregulation of IL-1 signaling is prominent among autoinflammatory conditions such as DIRA. Thus, Kineret has been successfully used and is indicated to treat DIRA. The approval was based on a natural-history study in nine patients (aged 1 month to 9 years at baseline) with genetically confirmed DIRA.¹ Patients were treated with Kineret for up to 10 years. All nine patients achieved remission while on Kineret for DIRA. In some patients, skin and bone manifestations resolved within days and weeks, respectively. Treatment with agents that block both IL- α and IL- β is recommended and includes Kineret and Arcalyst[®] (riloncept subcutaneous injection).²⁴

Rheumatoid Arthritis

Current recommendations for the treatment of rheumatoid arthritis from the American College of Rheumatology (ACR) [2021] do not make a recommendation for the use of Kineret.⁵ The recommendations also note that Kineret is used infrequently for rheumatoid arthritis and that TNFi and other non-TNFi biologics (i.e., rituximab, Actemra[®] [tocilizumab intravenous infusion, tocilizumab subcutaneous injection], and Orencia[®] [abatacept intravenous infusion, abatacept subcutaneous injection]) are appropriate initial biologic therapy for most patients with rheumatoid arthritis.

Systemic Juvenile Idiopathic Arthritis (SJIA)

The 2021 ACR Guideline for the treatment of juvenile idiopathic arthritis conditionally recommends biologic DMARDs (IL-1 and IL-6 blockers) as initial monotherapy for certain SJIA patients and note there is no preferred agent.⁶ Macrophage activation syndrome is a severe and potentially lethal complication associated with SJIA.⁷ Case series have shown rapid remission of macrophage activation syndrome as well as treatment of the underlying condition with the use of Kineret.

Still's Disease, Adult Onset (AOSD)

Still's disease presents in adults with features similar to those of SJIA.⁸ As in SJIA, Kineret has been effective in reducing fever, symptoms, and markers of inflammation in patients with adult-onset Still's disease who were refractory to conventional treatment with a corticosteroid, nonsteroidal anti-inflammatory drug (NSAID), and/or conventional synthetic DMARDs such as methotrexate.⁹⁻¹⁴

COVID-19

Guidelines from ACR recommend consideration of Kineret (>4 mg/kg/day) for children with hyperinflammation refractory to intravenous immunoglobulin and glucocorticoids, or in patients with contraindications to long-term use of glucocorticoids.²³ Kineret is also recommended in a similar population of children with multisystem inflammatory syndrome and features of macrophage activation syndrome associated with COVID-19.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Kineret. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Kineret as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Kineret to be prescribed by or in consultation with a physician who specializes in the condition being treated.

All reviews for use of Kineret for COVID-19 and/or cytokine release syndrome associated with COVID-19 will be forwarded to the Medical Director.

- **Kineret® (anakinra subcutaneous injection – Swedish Orphan Biovitrim)**

is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

1. Cryopyrin-Associated Periodic Syndromes. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i and ii):

- i. The medication is being used for treatment of neonatal onset multisystem inflammatory disease (NOMID), familial cold autoinflammatory syndrome (FCAS), Muckle-Wells Syndrome (MWS), and/or chronic infantile neurological cutaneous and articular (CINCA) syndrome; AND
- ii. The medication is prescribed by or in consultation with a rheumatologist, geneticist, or a dermatologist.

B) Patient is Currently Receiving Kineret. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on this medication for at least 6 months; AND Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).
- ii. Patient meets at least ONE of the following (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR
Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, amyloid A), reduction in proteinuria, and/or stabilization of serum creatinine.
 - b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as fewer cold-induced attacks; less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living.

2. Deficiency of Interleukin-1 Receptor Antagonist. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i and ii):
 - i. Genetic testing has confirmed a mutation in the *IL1RN* gene; AND
 - ii. The medication is prescribed by or in consultation with a rheumatologist, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders.
- B) Patient is Currently Receiving Kineret. Approve for 1 year if the patient meets BOTH of the following (i and ii):
 - i. Patient has been established on this medication for at least 6 months; AND Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least ONE of the following (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR
Note: Examples of objective measures include improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), reduction in proteinuria, and/or stabilization of serum creatinine.
 - b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as improvement of skin or bone symptoms; less joint pain/tenderness, stiffness, or swelling.

3. Rheumatoid Arthritis. Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i and ii):
- i. Patient has had a 3-month trial of a biologic OR targeted synthetic disease-modifying antirheumatic drug (DMARD) for this condition, unless intolerant; AND
Note: This is a 3-month trial of at least one biologic other than the requested drug. A biosimilar of the requested biologic does not count. Refer to [Appendix](#) for examples of biologics and targeted synthetic DMARDs used for rheumatoid arthritis. Conventional synthetic DMARDs such as methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine do not count.
 - ii. The medication is prescribed by or in consultation with a rheumatologist.
- B) Patient is Currently Receiving Kineret. Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least ONE of the following (a or b):
 - a) Patient experienced a beneficial clinical response when assessed by at least one objective measure; OR
Note: Examples of standardized and validated measures of disease activity include Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28 using erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), Patient Activity Scale (PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or Simplified Disease Activity Index (SDAI).
 - b) Patient experienced an improvement in at least one symptom, such as decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths.

Other Uses with Supportive Evidence

3. COVID-19 (Coronavirus Disease 2019). Forward all requests to the Medical Director.

Note: This includes requests for cytokine release syndrome associated with COVID-19.

Kineret has been granted Emergency Use Authorization (EUA) for treatment of Coronavirus disease 2019 (COVID-19) in hospitalized adults with positive viral testing with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR).²² The recommended dose under the EUA is 100 mg daily by subcutaneous injection for 10 days.

Additionally, guidelines from ACR recommend consideration of Kineret (>4 mg/kg/day) for children with COVID-19 and hyperinflammation refractory to intravenous immunoglobulin and glucocorticoids, or in patients with

contraindications to long-term use of glucocorticoids.²³ Initiation of Kineret prior to invasive mechanical ventilation may be beneficial. Kineret is also recommended in a similar population of children with multisystem inflammatory syndrome and features of macrophage activation syndrome associated with COVID-19. Per these guidelines, a prolonged course of immunomodulatory treatment extending for 2 or 3 weeks or longer may be necessary to avoid rebound inflammation.

4. Systemic Juvenile Idiopathic Arthritis (SJIA). Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the medication is prescribed by or in consultation with a rheumatologist.

B) Patient is Currently Receiving Kineret. Approve for 1 year if the patient meets BOTH of the following (i and ii):

i. Patient has been established on this medication for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).

ii. Patient meets at least ONE of the following (a or b):

a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR

Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement, or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.

b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living.

5. Still's Disease, Adult Onset. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i and ii):

i. Patient meets ONE of the following (a, b, or c):

a) Patient meets BOTH of the following [(1) and (2)]:

(1) Patient has tried one corticosteroid; AND

(2) Patient has had an inadequate response to one conventional synthetic disease-modifying antirheumatic drug (DMARD) such as methotrexate given for at least 2 months or was intolerant to a conventional synthetic DMARD; OR

Note: A previous trial of one biologic (e.g., Actemra [tocilizumab intravenous injection, tocilizumab subcutaneous injection], Arcalyst [rilonacept subcutaneous injection], Ilaris [canakinumab subcutaneous injection]) other than the requested drug also counts towards a trial of one other systemic agent for Still's disease. A biosimilar of the requested biologic does not count.

- b) Patient has at least moderate to severe active systemic features of this condition, according to the prescriber; OR
Note: Examples of moderate to severe active systemic features include fever, rash, lymphadenopathy, hepatomegaly, splenomegaly, and serositis.
 - c) Patient has active systemic features with concerns of progression to macrophage activation syndrome, as determined by the prescriber; AND
 - ii. The medication is prescribed by or in consultation with a rheumatologist.
- B) Patient is Currently Receiving Kineret. Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on this medication for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least ONE of the following (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR
Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.
 - b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

- **Kineret® (anakinra subcutaneous injection – Swedish Orphan Biovitrim)** is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. **Ankylosing Spondylitis.** Kineret has been beneficial in a few patients with ankylosing spondylitis, but results are not consistent.^{15,16} In a small open-label study, patients with active ankylosing spondylitis who were refractory to NSAIDs (n = 20) received Kineret 100 mg daily.¹⁶ The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score decreased over a 6-month period but was not significant (5.8 at baseline vs. 5.0 at Week 12, and 4.8 at Week 24). No significant change was found in Bath Ankylosing Spondylitis Functional Index (BASFI) and patients' and physicians' global assessment of general pain during the study. After 12 weeks, both the assessment in ankylosing spondylitis (ASAS) 20 and 40 responses improved in 10.5% of patients (intention-to-treat analysis). After 24 weeks, ASAS 20 was attained in 26% of patients, ASAS 40 in 21% of patients,

and ASAS 70 in 10.5% of patients. Guidelines for axial spondyloarthritis from the Assessment of SpondyloArthritis International Society (ASAS)/European Union Against Rheumatism (EULAR) [2016] do not mention Kineret as a treatment option.¹⁷

- 2. Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD).** Data are lacking evaluating concomitant use of Kineret in combination with another biologic or with a targeted synthetic DMARD used for an inflammatory condition (See [Appendix](#) for examples). Combination therapy with biologics and/or biologics + targeted synthetic DMARDs has a potential for a higher rate of adverse effects and lacks controlled trial data in support of additive efficacy.¹⁸

Note: This does NOT exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with Kineret.

- 4. Lupus Arthritis.** The effectiveness and safety of Kineret were evaluated in an open 3-month pilot trial in patients (n = 4) with systemic lupus erythematosus (SLE) and severe, therapy-refractory non-erosive polyarthritis (three patients had deforming Jaccoud's arthropathy) and no other uncontrolled major organ involvement.¹⁹ Patients were refractory to NSAIDs, antimalarials, corticosteroids, methotrexate, cyclophosphamide, and azathioprine. SLE was controlled with stable doses of corticosteroids and/or antirheumatic or immunosuppressive agents; pain was managed with NSAIDs and/or other medications. Patients had improved clinically after 4 weeks on Kineret, but after 12 weeks, the clinical activity parameters tended to increase again. The results from this study are preliminary and a larger controlled study is needed.

- 5. Osteoarthritis.** In a Phase II study in patients with painful osteoarthritis of the knee, Kineret 150 mg administered by intraarticular injection was well tolerated.²⁰ The study was not designed to assess the analgesic efficacy of Kineret. Patients with osteoarthritis of the knee were enrolled in a multicenter, double-blind, placebo-controlled study and randomized to Kineret 50 mg, Kineret 150 mg, or placebo for intraarticular injection.²¹ Although the injections were well tolerated, there were no significant differences in improvement in knee pain, stiffness, function or cartilage turnover between Kineret doses and placebo. Similar to other studies in this population, there was a significant placebo effect noted.

REFERENCES

1. Kineret[®] subcutaneous injection [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum; December 2020.
2. Shinkai K, McCalmont TH, Leslie KS. Cryopyrin-associated periodic syndromes and autoinflammation. *Clin Exp Dermatol.* 2008;33:1-9.
3. Ozen S, Hoffman HM, Frenkel J, et al. Familial Mediterranean Fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005. *Ann Rheum Dis.* 2006;65:961-964.
4. Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra. *J Pediatr.* 2010;157(2):310-315.
5. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken).* 2021;73(7):924-939.

6. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. *Arthritis Rheumatol*. 2022;74(4):553-569.
7. Boom V, Anton J, Lahdenne P, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. *Pediatr Rheumatol Online J*. 2015;13(1):55.
8. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. *Clin Exp Rheumatol*. 2011;29(2):331-336.
9. Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminary experience in France. *Ann Rheum Dis*. 2008;67:302-308.
10. Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. *Arthritis Rheum*. 2005;52:1794-1803.
11. Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: Four case reports with serial cytokine measurements and a review of the literature. *Semin Arthritis Rheum*. 2007;37:189-197.
12. Kallioliadis GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. *Ann Rheum Dis*. 2007;66:842-843.
13. Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. *Arthritis Care Res (Hoboken)*. 2013;65(5):822-826.
14. Ortiz-Sanjuán F1, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. *Medicine (Baltimore)*. 2015;94(39):e1554.
15. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. *Ann Rheum Dis*. 2004;63:1041-1045.
16. Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis*. 2005;64:296-298.
17. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017;76(6):978-991.
18. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis*. 2013;72 Suppl 2:ii2-34.
19. Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. *Ann Rheum Dis*. 2005;64:630-683.
20. Chevalier X, Giraudeau B, Conrozier T, et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. *J Rheumatol*. 2005;32:1317-1323.
21. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*. 2009;61(3):344-352.
22. US Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Kineret. November 2022. Available at: <https://www.fda.gov/media/163075/download>. Accessed on February 22, 2024.
23. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. *Arthritis Rheumatol*. 2022 Apr;74(4):e1-e20.
24. Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. *Ann Rheum Dis*. 2022;81(7):907-921.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	01/25/2023
Annual Revision	No criteria changes.	02/28/2024
Selected Revision	<p>Systemic Juvenile Idiopathic Arthritis: The requirement for previous therapy was removed. Exceptions that apply to a patient who is not required to try another therapy prior to Kineret were removed (no longer needed).</p> <p>Still's Disease, Adult Onset: The condition was changed to as listed (previously was Still's Disease).</p>	04/24/2024

APPENDIX

	Mechanism of Action	Examples of Inflammatory Indications*
Biologics		
Adalimumab SC Products (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
Cimzia® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
Etanercept SC Products (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA
Zymfentra® (infliximab-dyyb SC injection)	Inhibition of TNF	CD, UC
Infliximab IV Products (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
Simponi®, Simponi® Aria™ (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC
		IV formulation: AS, PJIA, PsA, RA
Actemra® (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA
		IV formulation: PJIA, RA, SJIA
Kevzara® (sarilumab SC injection)	Inhibition of IL-6	RA, PMR
Orencia® (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA
		IV formulation: JIA, PsA, RA
Rituximab IV Products (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
Kineret® (anakinra SC injection)	Inhibition of IL-1	JIA [^] , RA
Stelara® (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
Siliq™ (brodalumab SC injection)	Inhibition of IL-17RA	PsO
Bimzelx® (bimekizumab-bkzx SC injection)	Inhibition of IL-17A and IL-17F	PsO
Cosentyx® (secukinumab SC injection, secukinumab IV infusion)	Inhibition of IL-17A	SC formulation: AS, ERA, nr-axSpA, PsO, PsA
		IV formulation: AS, nr-axSpA, PsA
Taltz® (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
Ilumya™ (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
Skyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)	Inhibition of IL-23	SC formulation: CD, PSA, PsO
		IV formulation: CD
Tremfya™ (guselkumab SC injection)	Inhibition of IL-23	PsO
Entyvio™ (vedolizumab IV infusion, vedolizumab SC injection)	Integrin receptor antagonist	SC formulation: UC
		IV formulation: CD, UC
Oral Therapies/Targeted Synthetic DMARDs		
Otezla® (apremilast tablets)	Inhibition of PDE4	PsO, PsA
Cibinqo™ (abrocitinib tablets)	Inhibition of JAK pathways	AD
Olumiant® (baricitinib tablets)	Inhibition of JAK pathways	RA
Rinvoq® (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, nr-axSpA, RA, PsA, UC
Sotyktu™ (deucravacitinib tablets)	Inhibition of TYK2	PsO

Xeljanz® (tofacitinib tablets)	Inhibition of JAK pathways	RA, PJIA, PsA, UC
Xeljanz® XR (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC

* Not an all-inclusive list of indications (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; PMR – Polymyalgia rheumatic; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; TYK2 – Tyrosine kinase 2.

"CIGNA COMPANIES" REFERS TO OPERATING SUBSIDIARIES OF THE CIGNA GROUP. ALL PRODUCTS AND SERVICES ARE PROVIDED EXCLUSIVELY BY OR THROUGH SUCH OPERATING SUBSIDIARIES, INCLUDING CIGNA HEALTH AND LIFE INSURANCE COMPANY, CONNECTICUT GENERAL LIFE INSURANCE COMPANY, EVERNORTH BEHAVIORAL HEALTH, INC., CIGNA HEALTH MANAGEMENT, INC., AND HMO OR SERVICE COMPANY SUBSIDIARIES OF THE CIGNA GROUP. © 2024 THE CIGNA GROUP.